Co-Diagnostics Introduces its CoPrimer Technology and Applications at MEDICA 2022

Co-Diagnostics, Inc. (Salt Lake City, UT, USA), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, is hosting a booth at the MEDICA 2022 trade fair in Düsseldorf, Germany from 14-17 November. After more than 40 years, MEDICA has become the largest medical trade fair in the world, attracting thousands of exhibitors from more than 50 countries. The company is using the opportunity to generate increased interest in its suite of in vitro diagnostic and research products for COVID-19 and other infectious diseases, and to introduce and promote its CoPrimer technology and applications to a wide audience of international attendees.

Co-Diagnostics’ revolutionary CoPrimer PCR technology is available around the world at cost-efficient pricing. The unique, proprietary structure of CoPrimers molecules creates reactions that are far more specific than competing PCR technologies, to better identify the presence of and distinguish between viruses, pathogens, cancer, or other attributes in agricultural or industrial applications. One of the most important attributes of Co-Diagnostics’ CoPrimer technology is the virtual elimination of “primer-dimers,” the principal source of false positives in diagnostic testing. Primer-dimers are essentially the amplification of errors that can take place during the course of a molecular diagnostic test. These errors dramatically minimize the accuracy of the test and lead to false results and/or inaccurate diagnoses. By virtually eliminating “primer-dimers” from molecular diagnostic testing, CoPrimers assure unparalleled performance of real-time PCR molecular tests.

CoPrimers’ specificity also enables the identification of a broad spectrum of conditions in a single molecular diagnostic test procedure – known as multiplexing – as opposed to conducting discrete individual procedures. Multiplexing enables a single test to identify numerous conditions, attributes, or genetic sequences simultaneously. Multiplexing has enormous implications on cost-efficiencies and time savings in molecular testing, which could prove substantial in a medical situation.

At MEDICA 2022, Co-Diagnostics is also introducing its upcoming Co-Dx PCR Home platform that is powered by the cloud, which is intended to allow for the results to even be transmitted to different destinations as needed. The platform is being designed with the capability to test for a wide variety of diseases and is in line with the company’s aim to disrupt the molecular diagnostics status quo by bringing revolutionary lab-grade PCR testing capabilities - the gold standard in infectious disease testing - into homes and businesses.

Related Links:
Co-Diagnostics, Inc.

Visit expo >

Gold Member

Turnkey Packaging Solution

HLX

Antipsychotic TDM AssaysSaladax Antipsychotic Assays

New

Rocking Shaker

HumaRock

New

Nuclear Matrix Protein 22 Test

NMP22 Test